Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan.
J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):23-5. doi: 10.1007/s00534-010-0305-1.
We developed a novel cell therapy, autologous bone marrow cell infusion (ABMi) therapy, using autologous bone marrow, for liver cirrhosis patients. Our study depends on the findings from basic studies that bone marrow cell infusion repairs liver fibrosis in the cirrhotic liver, and improves liver function and the survival rate. Beginning in November 2003, we started a clinical study and found that ABMi therapy was safe and effective for liver cirrhosis patients. Multicenter trials in Japan and Korea have also shown the effectiveness of ABMi therapy. In this review, we report the current status of ABMi therapy for liver cirrhosis patients.
我们开发了一种新的细胞疗法，即使用自体骨髓的自体骨髓细胞输注（ABMi）疗法，用于肝硬化患者。我们的研究基于这样的基础研究结果，即骨髓细胞输注可修复肝硬化肝脏中的肝纤维化，并改善肝功能和生存率。从 2003 年 11 月开始，我们开始了一项临床研究，发现 ABMi 疗法对肝硬化患者是安全有效的。日本和韩国的多中心试验也表明了 ABMi 疗法的有效性。在这篇综述中，我们报告了 ABMi 疗法治疗肝硬化患者的现状。
Zotero 插件